<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01396135</url>
  </required_header>
  <id_info>
    <org_study_id>A3331019</org_study_id>
    <nct_id>NCT01396135</nct_id>
  </id_info>
  <brief_title>A Phase 1 Study To Investigate The Pharmacokinetics, Safety And Tolerability Of CP-601,927 In Healthy Japanese Subjects</brief_title>
  <official_title>A Phase 1, Randomized, Subject- And Investigator-blind, Sponsor-open, Placebo-controlled, Single- And Multiple-dose Study To Investigate The Pharmacokinetics, Safety And Tolerability Of Cp-601,927 In Healthy Japanese Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This Phase 1 study is the first clinical trial to be conducted in Japanese subjects. The
      pharmacokinetics, safety and tolerability of single and multiple doses of CP-601,927 will be
      evaluated in Japanese, healthy, non-smoking subjects.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <start_date type="Actual">August 26, 2011</start_date>
  <completion_date type="Anticipated">October 29, 2011</completion_date>
  <primary_completion_date type="Anticipated">October 29, 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax, AUClast, AUC0-12, Tmax and as data permit AUCinf, t1/2, CL/F, Vd/F after single dose of 1 mg CP-601,927</measure>
    <time_frame>0,0.5,1,2,4,6,8,12,14,16,24,36,48 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax, AUClast, AUC0-12, Tmax and as data permit AUCinf, t1/2, CL/F, Vd/F after single dose of 2 mg CP-601,927</measure>
    <time_frame>0,0.5,1,2,4,6,8,12,14,16,24,36,48 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax, AUClast, AUC0-12, Tmax and as data permit AUCinf, t1/2, CL/F, Vd/F after single dose of 3 mg CP-601,927</measure>
    <time_frame>0,0.5,1,2,4,6,8,12,14,16,24,36,48 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Ctrough, Cmax, AUC0-12, Tmax and as data permit t1/2, CL/F and Rac (accumulation ratio) based on Cmax and AUC0-12 after multiple doses of CP-601,927 given as 2 mg BID (4mg/day) for 7 days</measure>
    <time_frame>Day1-7</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Suicidality assessment after single dose of 1 mg CP-601,927</measure>
    <time_frame>Day 0, 0 and 2 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Suicidality assessment after single dose of 2 mg CP-601,927</measure>
    <time_frame>Day 0, 0 and 2 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Suicidality assessment after single dose of 3 mg CP-601,927</measure>
    <time_frame>Day 0, 0 and 2 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Suicidality assessment after multiple doses of CP-601,927 given as 2 mg BID (4mg/day) for 7 days</measure>
    <time_frame>Day1-7</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Single dosing</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single doses of CP-601,927 (1, 2 or 3 mg) or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Multiple dosing</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple doses of CP-601,927 (2 mg BID, 4mg/day) or placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CP-601,927</intervention_name>
    <description>Single dose of 1 mg CP-601,927 given as oral 1 mg tablets</description>
    <arm_group_label>Single dosing</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CP-601,927</intervention_name>
    <description>Single dose of 2 mg CP-601,927 given as oral 1 mg tablets</description>
    <arm_group_label>Single dosing</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CP-601,927</intervention_name>
    <description>Single dose of 3 mg CP-601,927 given as oral 1 mg tablets</description>
    <arm_group_label>Single dosing</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Single dose of placebo given as a matching number of oral tablets</description>
    <arm_group_label>Single dosing</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CP-601,927</intervention_name>
    <description>Multiple doses of CP-601,927 given as 2 mg BID (4 mg/day) as oral 1 mg tablets for 7 days</description>
    <arm_group_label>Multiple dosing</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Multiple doses of placebo given as a matching number of oral tablets</description>
    <arm_group_label>Multiple dosing</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male and/or female Japanese subjects between the ages of 18 and 55 years,
             inclusive.

          -  Japanese defined as being able to document that all 4 grandparents were Japanese and
             were born in Japan.

          -  Body Mass Index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight &gt;50 kg (110 lbs).

        Exclusion Criteria:

          -  Evidence or history of clinically significant hematological, renal, endocrine,
             pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or
             allergic disease (including drug allergies, but excluding untreated, asymptomatic,
             seasonal allergies at the time of dosing).

          -  Females of childbearing potential.

          -  Subjects with regular (daily or weekly) use of tobacco products or nicotine currently
             or within the past 6 months. Subjects with urine cotinine concentrations &gt;100 ng/mL at
             any time during the study will be excluded.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A3331019&amp;StudyName=A%20Phase%201%20Study%20To%20Investigate%20The%20Pharmacokinetics%2C%20Safety%20And%20Tolerability%20Of%20CP-601%2C927%20In%20Healthy%20Japanese%20Subjects</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>July 14, 2011</study_first_submitted>
  <study_first_submitted_qc>July 14, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 18, 2011</study_first_posted>
  <last_update_submitted>October 27, 2018</last_update_submitted>
  <last_update_submitted_qc>October 27, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 30, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Phase 1</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Healthy</keyword>
  <keyword>Japanese</keyword>
  <keyword>Non-smokers</keyword>
  <keyword>Major Depressive Disorder</keyword>
  <keyword>CP-601</keyword>
  <keyword>927</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Information relating to our policy on data sharing and the process for requesting data can be found at the following link: http://www.pfizer.com/research/clinical_trials/trial_data_and_results/data_requests</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

